A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
← catalyst calendarNCT07096843 · readout ≤ 437 d
Sponsored by Climb Bio, Inc. (industry) · CLYM — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
45estimated
Sites
43
Countries
Argentina, Brazil, Chile +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-25 | actual | When the study began enrolling |
| Primary completion | Oct 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Primary Membranous Nephropathy
Intervention
- Drug: budoprutug — also filed as TNT119
Primary outcome
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events (TEAEs)
measured Up to Week 48
Permalink · CLYM's whole pipeline · Catalyst calendar · Every registered study · What changed